OraNera: Withdrawal of the marketing authorisation application


On 14 March 2013, CellSeed Europe Ltd. officially notified the European Medicines Agency that it wishes to withdraw its application for a marketing authorisation for OraNera (previously known as Caomecs), intended for the treatment of limbal-stem-cell deficiency in adults.

Key facts

Product number
Date of withdrawal
Company making the application
CellSeed Europe Ltd
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating
2 ratings